Niagen's NR Study: A 2.5-Year Drop in Muscle Epigenetic Age

A new peer-reviewed analysis in Aging Cell links Niagen Bioscience’s nicotinamide riboside (NR) supplement to a roughly 2.5-year reduction in skeletal muscle epigenetic age — a striking number that comes with an unusually blunt caveat from the company that funded it: the findings are preliminary and largely correlational.

What the Study Found

NR itself isn’t new to the supplement market — it’s one of the more established NAD+ precursors, sold for years on the general premise of supporting cellular energy metabolism as people age. What’s new in this particular release is the attempt to tie that mechanism to a measurable outcome using epigenetic clocks, rather than resting on NAD+ levels alone as the evidence.

The analysis pooled skeletal muscle and blood samples from three prior clinical studies with new laboratory experiments, then scored epigenetic age across seven established clocks, including the muscle-specific MEAT clock. Six of the seven skeletal-muscle clocks trended toward lower epigenetic age in NR-supplemented samples, with the MEAT clock showing the headline ~2.5-year reduction; one clock, PCGrimAge, moved the opposite direction. In blood, results were more consistent: two clocks, DunedinPACE and PCHannum, showed statistically significant reductions. In one of the underlying trials, participants took 1,000 mg per day of Niagen NR for five months. Separately, in-vitro lab work found NR raised NAD+ levels in human muscle cells (myotubes) by 1.52-fold, though researchers observed no significant change in mitochondrial DNA quantity in that experiment.

Why the Caveats Matter as Much as the Number

Niagen Bioscience funded and published this analysis, and the company’s own statement is notably direct about its limits — the findings are preliminary, largely correlational, and require further research before anyone treats a 2.5-year clock shift as a validated outcome. That framing matters for two reasons. First, epigenetic clocks are still an evolving measurement tool: six clocks moving one direction and one moving the other isn’t unusual noise, but it’s also not the kind of unanimous signal that settles a scientific question. Second, a company-funded, pooled-and-reanalyzed dataset is a different standard of evidence than an independent, pre-registered trial designed from the outset to test this specific outcome — a distinction Stack Archive has flagged before in its coverage of Niagen’s broader NR market position. Neither point erases the result, but both are reasons to treat “epigenetic age reduction” as a promising early signal rather than a settled claim about what NR supplementation does to biological aging.

It’s also worth naming what the two significant blood-clock results, DunedinPACE and PCHannum, actually measure differently than the muscle-specific MEAT clock: they’re built from different underlying biological signals and validated against different aging outcomes, so a reduction on one doesn’t automatically imply the same magnitude of effect on another. Seeing movement across both tissue types and multiple clock families is a more interesting signal than a single clock moving on its own, but “more interesting” is still a long way from “clinically established.”

Source: Longevity.Technology

Content created with AI assistance and reviewed for accuracy.